INM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	476 022
Average Volume	377 841
Market Cap	1.39M
EPS	$0 ( 2024-02-16 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.550
ATR14	$0.00400 (1.74%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-14	Hull Andrew	Sell	42	Employee Stock Option (Expiration)
2024-03-04	Hsu Eric C	Sell	309	Employee Stock Option (Expiration)
2024-01-21	Mancini Alexandra Diane Janet	Sell	121	Employee Stock Option (Expiration)
2024-02-20	Jagpal Netta	Sell	50 000	Employee Stock Option (Right to Buy)
2024-02-21	Hull Andrew	Buy	37 500	Common Stock

INSIDER POWER
74.56
Last 93 transactions
Buy: 1 291 573 \| Sell: 391 310

Volume Correlation

Long: -0.25 (neutral)

Short: 0.53 (weak)

Signal:(43.503) Neutral

InMed Pharmaceuticals Correlation

10 Most Positive Correlations
ZSAN	0.901
KBSF	0.889
BNOX	0.885
ARQQ	0.884
AYLA	0.884
VIH	0.884
LYRA	0.882
QLGN	0.881
LQDT	0.879
DWACU	0.87

10 Most Negative Correlations
STAY	-0.89
AVGO	-0.884
TIPT	-0.883
BNIXU	-0.876
TVTY	-0.875
ARDX	-0.874
USLM	-0.872
LRFC	-0.869
LUNA	-0.864
PEBK	-0.862

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

InMed Pharmaceuticals Correlation - Currency/Commodity

0.31
( neutral )

0.11
( neutral )

0.00
( neutral )

-0.64
( weak negative )

InMed Pharmaceuticals Financials

Annual	2023
Revenue:	$4.14M
Gross Profit:	$1.40M (33.93 %)
EPS:	$-3.25

FY	2023
Revenue:	$4.14M
Gross Profit:	$1.40M (33.93 %)
EPS:	$-3.25

FY	2022
Revenue:	$1.09M
Gross Profit:	$543 546 (49.89 %)
EPS:	$-41.74

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-38.00

Financial Reports:

No articles found.

InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.